Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. Show More...

  • Website https://www.regulusrx.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 7.93 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -727.4 -1029.84 -25.44 -5.88 -15.48 -12.96 -18.59 -11.47 -5.59 -1.08 -1.02
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 3.0 4.0 4.0 4.0 6.0 9.0 17.0 21.0
    Book Value Per Share * USD 20.79 27.12 18.16 28.68 16.48 5.61 0.17 -0.010 0.54
    Free Cash Flow Per Share * USD -14.83 -6.44 -10.8 -10.9 -13.69 -12.15 -5.81 -1.34
    Return on Assets % -17.73 -23.78 -16.48 -38.49 -35.67 -67.7 -80.58 -92.13 -53.11 -77.51
    Financial Leverage (Average) 1.67 1.32 1.29 1.14 1.8 2.21 2.1 2.35
    Return on Equity % -169.02 -24.0 -50.28 -43.54 -90.85 -157.53 -331.78 -262.65 -481.74
    Return on Invested Capital % -83.9 -21.39 -41.8 -44.16 -74.17 -106.77 -143.88 -76.32 -101.44
    Interest Coverage -42.06 -18.06 -69.52 -518.19 -68.24 -25.48 -19.76 -7.72 -9.42
    Current Ratio 3.0 7.75 11.3 4.69 10.63 6.34 2.05 0.72 1.87 1.7
    Quick Ratio 2.97 7.68 11.0 4.54 9.82 5.63 1.85 0.52 1.63 1.45
    Debt/Equity 0.16 0.12 0.35